The Thyroid Cancer Testing Program is designed to provide access to molecular testing for appropriate patients, 12 years of age and older with:

- advanced or metastatic medullary thyroid cancer (MTC) who require systemic therapy, or
- advanced or metastatic non-medullary thyroid cancer (non-MTC) who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)

Appropriate patients are eligible for one molecular test at no cost for the purpose of determining whether the patient has any actionable genetic alterations that may inform therapeutic decisions, without regard to the purchase of any prescribed drug or any other product.*

*Eligible patient may receive either one (1) NGS thyroid profile test (for MTC) or one (1) NGS thyroid profile plus RET FISH test (for non-MTC), regardless of test results or treatment decision. No patient, healthcare program, payer, or beneficiary shall be billed for these tests. The tests shall not be included in a bundled payment to any healthcare facility including, but not limited to, a hospital. The ordering physician shall not be compensated any fees in connection with this testing, such as for specimen collection, handling, or data reporting. Program is not valid where prohibited by law. Eli Lilly and Company reserves the right to rescind, revoke, or amend the program for any reason without notice.

The Thyroid Cancer Testing Program is NOT available to New York State patients and facilities, as the aforementioned NGS tests have not been approved by the New York State Department of Health.

FISH=fluorescence in situ hybridization; NGS=next-generation sequencing; RET=rearranged during transfection.